Validation of Electronic Data on Chemotherapy and Hormone Therapy Use in HMOs
- 1 October 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 51 (10) , e67-e73
Abstract
Background: Most data regarding medical care for cancer patients in the United States comes from Surveillance, Epidemiology and End Results-linked Medicare analyses of individuals aged 65 years or older and typically excludes Medicare Advantage enrollees. Objectives: To assess the accuracy of chemotherapy and hormone therapy treatment data available through the Cancer Research Network’s Virtual Data Warehouse (VDW). Research Design: Retrospective, longitudinal cohort study. Medical record-abstracted, tumor registry-indicated treatments (gold standard) were compared with VDW-indicated treatments derived from health maintenance organization pharmacy, electronic medical record, and claim-based data systems. Subjects: Enrollees aged 18 years and older diagnosed with incident breast, colorectal, lung, or prostate cancer from 2000 through 2007. Measures: Sensitivity, specificity, and positive predictive value were computed at 6 and 12 months after cancer diagnosis. Results: Approximately 45% of all cancer cases (total N=23,800) were aged 64 years or younger. Overall chemotherapy sensitivity/specificities across the 3 health plans for incident breast, colorectal, lung, and prostate cancer cases were 95%/90%, 95%/93%, 93%/93%, and 85%/77%, respectively. With the exception of prostate cancer cases, overall positive predictive value ranged from 86% to 89%. Small variations in chemotherapy data accuracy existed due to cancer site and data source, whereas greater variation existed in hormone therapy capture across sites. Conclusions: Strong concordance exists between gold standard tumor registry measures of chemotherapy receipt and Cancer Research Network VDW data. Health maintenance organization VDW data can be used for a variety of studies addressing patterns of cancer care and comparative effectiveness research that previously could only be conducted among elderly Surveillance, Epidemiology and End Results-Medicare populations.Keywords
This publication has 22 references indexed in Scilit:
- Age, Comorbidity, and Breast Cancer Severity: Impact on Receipt of Definitive Local Therapy and Rate of Recurrence among Older Women with Early-Stage Breast CancerJournal of the American College of Surgeons, 2011
- Accuracy and Complexities of Using Automated Clinical Data for Capturing Chemotherapy AdministrationsMedical Care, 2009
- The Cardiovascular Research NetworkCirculation: Cardiovascular Quality and Outcomes, 2008
- Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2008
- Mammography Surveillance and Mortality in Older Breast Cancer SurvivorsJournal of Clinical Oncology, 2007
- Correlates of screening sigmoidoscopy use among men in a large nonprofit health planCancer, 2007
- Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research NetworkBreast Cancer Research and Treatment, 2007
- Criterion Validity of Medicare Chemotherapy Claims in Cancer and Leukemia Group B Breast and Lung Cancer Trial ParticipantsJNCI: Journal of the National Cancer Institute, 2005
- Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon CancerJournal of Clinical Oncology, 2002
- Construct Validity of Medicare Chemotherapy ClaimsMedical Care, 2002